Leidos

1) Strong Financial Performance - Q2 revenue increased 7% YoY, reaching a record $4.6 billion, with 4% organic growth. - Adjusted EBITDA margin remained robust at 13.8%. - Operating cash flow set a Q2 record at nearly $800 million, with free cash flow of $761 million. - Book-to-bill ratio was 1.1, with $5 billion in net awards, indicating strong future bookings momentum.

2) Segment Highlights and Developments - Defense: Revenue growth accelerated to 6% organically, with a book-to-bill ratio of 2.2 for Q2. Major contracts include a $1 billion agreement for munitions and ongoing work on unmanned surface vessels and missile tracking satellites. - Health: Demand for VBA medical disability exams remains strong, but incentive payments have been suspended for the rest of the year. The company is preparing for a recompete in 2027. - Homeland: Led all segments with 32% total growth and 15% organic growth, driven by energy infrastructure and air traffic management.

3) Challenges and Headwinds - The suspension of incentive payments in the Health segment due to administrative reviews by the VA could impact margins and profitability in the short term. - The transition to fixed-price contracts in the Intelligence and Digital segment may pose risks if not managed effectively. - Potential delays in the RFP process for the VBA contract could create uncertainty in revenue expectations for 2027.

4) Strategic Outlook and Guidance - The company raised its 2026 revenue guidance midpoint by $100 million and EPS guidance by $0.05, reflecting confidence in ongoing growth. - Expected organic revenue growth of approximately 7% and adjusted EBITDA growth of 19% in 2026. - Continued focus on diversifying earnings through investments in Defense Tech, energy, and cyber growth pillars, while maintaining a low capital intensity business model.

5) Investor Considerations - The earnings call did not provide specific figures on the expected impact of the VBA recompete on margins for 2027, leaving some uncertainty for investors. - The company is positioned to leverage its strengths in technology and quality to maintain competitiveness in the Health segment despite current challenges.

Bottom line: Leidos demonstrated strong financial results in Q2 2026, with solid growth across segments, particularly in Defense and Homeland. While facing challenges in the Health segment, the company is well-positioned to capitalize on its NorthStar 2030 strategy, raising guidance and maintaining a focus on sustainable growth, making it an attractive prospect for shareholders.